OptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of OptimizeRx Co. (NASDAQ:OPRX) have received an average rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $9.06.

OPRX has been the topic of several research analyst reports. Stephens assumed coverage on OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target on the stock. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research report on Tuesday, December 24th. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price objective on shares of OptimizeRx in a research report on Thursday, February 6th. B. Riley raised OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th.

Insiders Place Their Bets

In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of the business’s stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the transaction, the director now owns 389,452 shares in the company, valued at $2,959,835.20. This trade represents a 472.35 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC raised its position in shares of OptimizeRx by 358.5% during the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after acquiring an additional 21,060 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after acquiring an additional 2,414 shares during the last quarter. Royce & Associates LP acquired a new position in shares of OptimizeRx in the 4th quarter valued at $5,198,000. SG Americas Securities LLC bought a new stake in shares of OptimizeRx in the fourth quarter worth about $51,000. Finally, Perkins Capital Management Inc. increased its stake in OptimizeRx by 4.4% during the 4th quarter. Perkins Capital Management Inc. now owns 105,813 shares of the company’s stock worth $514,000 after purchasing an additional 4,450 shares in the last quarter. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Price Performance

NASDAQ OPRX opened at $8.13 on Friday. OptimizeRx has a 1 year low of $3.78 and a 1 year high of $14.13. The company has a fifty day simple moving average of $6.86 and a 200 day simple moving average of $6.02. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The company has a market cap of $150.32 million, a P/E ratio of -6.11 and a beta of 1.18.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.